An open-label, uncontrolled, multi-center phase II study to investigate efficacy and safety of ONO-4538 in patients with uterine cervical cancer, uterine corpus cancer, and soft-tissue sarcoma

Trial Profile

An open-label, uncontrolled, multi-center phase II study to investigate efficacy and safety of ONO-4538 in patients with uterine cervical cancer, uterine corpus cancer, and soft-tissue sarcoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Cervical cancer; Soft tissue sarcoma; Uterine cancer
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 05 Jun 2018 Primary endpoint (Overall response rate in patients with advanced or recurrent uterine cervical or corpus cancer) has been met.
    • 05 Jun 2018 Results (n=43) assessing efficacy and safety of nivolumab in patients with advanced or recurrent uterine cervical or corpus cancer, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 22 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top